In order for Japan to take fullest advantage of this new technology in drug discovery and regenerative medicine applications, the promotion of the seamless translation of fundamental research to preclinical and clinical applications will be of central importance. To meet these needs, the university appointed a launch committee in December of last year to consult on the founding principles, regulations, and faculty appointments for the new institute. On March 1, the Kyoto University executive board confirmed the set of regulations relating to the launch of the new institute, and formally approved the establishment of the new CiRA.

This formal recognition of CIRA as a university-affiliated institute facilitates many aspects of its operations, including the shoring up of faculty appointments and more secure research administration. Furthermore, in order to strengthen the research program and reorganize the programs of preclinical and clinical studies, a total of 18 research leaders will be appointed in the new CiRA. Support for fundamental research will continue through close, ongoing interactions with iCeMS. Educational contributions will be made possible by the acceptance of master's and doctoral degree students into CiRA departments in cooperation with Kyoto University graduate programs. The Research Strategy Division and the Support office will further be established to support the research divisions.

The new institute is supported through operational funds, research grants and donations from the private sector. In the 2010 fiscal year, CiRA will have approximately 120 academic, research and technical staff and a budget of around 2 billion yen. By fiscal 2012, CiRA is expected to grow to a staff of approximately 200, in keeping with the growth of this exciting field of research.